

# R&D Pipeline<sup>1</sup>

| Key Clinical Programs   | Phase 1 | Phase 2 | Phase 3 | Approval/Launch | Notes   |
|---|---------|---------|---------|-----------------|---|
| <b>DERMATOLOGY</b>  |         |         |         |                 |   |
| <b>CABTREO®</b><br>First triple combination product for the treatment of acne vulgaris                                      |         |         |         |                 | U.S. commercial launch 1Q 2024<br>New Drug Submission was submitted to Health Canada on May 30, 2023  |
| <b>SALIX</b>  |         |         |         |                 |   |
| <b>RED-C</b><br>Prevention and delay of first episode of hepatic encephalopathy   |         |         |         |                 | Enrollment of both RED-C global Phase 3 trials complete; currently in treatment phase   |
| <b>Amiselimod (S1P modulator):</b><br>Treatment for mild to moderate ulcerative colitis                                     |         |         |         |                 | Met with FDA for end of Phase 2 meeting and Phase 3 planning; meetings with EMEA and Japan authorities anticipated later in 2024<br>Phase 2 results to be presented at DDW in May<br>Evaluation of Phase 2 study for Crohn's in process |
| <b>SOLTA MEDICAL</b>  |         |         |         |                 |   |
| <b>Thermage® FLX</b><br>Radio-frequency technology to help tighten and improve the smoothness and texture of skin's surface |         |         |         |                 | Received National Medical Products Administration (NMPA) approval in China in January 2024  |
| <b>Clear + Brilliant® Touch</b><br>Fractionated laser device for skin rejuvenation  |         |         |         |                 | First approvals outside of the US, in New Zealand (March) and Australia (April)<br>Planned regulatory submissions on track for Europe, Canada, and additional Asia Pacific markets in 2024  |
| <b>Next Generation Fraxel®</b><br>Fractionated laser device for skin resurfacing  |         |         |         |                 | FDA submission planned for 2Q 2024<br>Approval could occur in 2H 2024   |

On track with our key R&D initiatives

1. Progress timelines are for illustrative purposes only